Conditional Ccnd1 Overexpression in Pax7+ Muscle Stem Cells
Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link:
Access Free Full Text.
Corresponding Organization :
Other organizations : Stanford University
Protocol cited in 1 other protocol
Variable analysis
- Presence or absence of the K112E mutation in the human Ccnd1 transgene under TRE regulation
- MuSCs isolated on the eighth day based on immunophenotype via FACS
- All transgenic animals were treated for seven days with doxycycline by providing doxycycline hyclate chow (Envigo, TD.120769), delivering a daily dose of 2-3 mg doxycycline based on consumption of 4-5 grams each day
- On the sixth and seventh days, doxycycline hyclate (Thermo Fisher ICN19895510) was injected intraperitoneally at 50 mg/kg in 0.9% NaCl
- Positive control: TRE-Ccnd1^WT mice transgenic for wild-type human Ccnd1 under TRE regulation
- Negative control: Not explicitly mentioned
Annotations
Based on most similar protocols
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!